Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram‐Negative Pathogens
- 20 July 2017
- journal article
- research article
- Published by Wiley in Angewandte Chemie-International Edition
- Vol. 56 (41), 12760-12764
- https://doi.org/10.1002/anie.201705913
Abstract
Antibiotic discovery and development is challenging as chemical scaffolds of synthetic origin often lack the required pharmaceutical properties, and the discovery of novel ones from natural sources is tedious. Herein, we report the discovery of new cystobactamids with a significantly improved antibacterial profile in a detailed screening of myxobacterial producer strains. Some of these new derivatives display antibacterial activities in the low‐μg mL−1 range against Gram‐negative pathogens, including clinical isolates of Klebsiella oxytoca, Pseudomonas aeruginosa, and fluoroquinolone‐resistant Enterobacteriaceae, which were not observed for previously reported cystobactamids. Our findings provide structure–activity relationships and show how pathogen resistance can be overcome by natural scaffold diversity. The most promising derivative 861‐2 was prepared by total synthesis, enabling further chemical optimization of this privileged scaffold.Keywords
This publication has 22 references indexed in Scilit:
- Natural products from myxobacteria: novel metabolites and bioactivitiesNatural Product Reports, 2016
- Isolation of Coralmycins A and B, Potent Anti-Gram Negative Compounds from the Myxobacteria Corallococcus coralloides M23Journal of Natural Products, 2016
- Natural Products as Sources of New Drugs from 1981 to 2014Journal of Natural Products, 2016
- A new antibiotic kills pathogens without detectable resistanceNature, 2015
- Cystobactamids: Myxobacterial Topoisomerase Inhibitors Exhibiting Potent Antibacterial ActivityAngewandte Chemie-International Edition, 2014
- Cystobactamide: Topoisomerase-Inhibitoren aus Myxobakterien mit hoher antibakterieller AktivitätAngewandte Chemie, 2014
- An analysis of FDA-approved drugs for infectious disease: antibacterial agentsDrug Discovery Today, 2014
- Challenges of Antibacterial DiscoveryClinical Microbiology Reviews, 2011
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Drugs for bad bugs: confronting the challenges of antibacterial discoveryNature Reviews Drug Discovery, 2006